Led · Series D · Feb 2026

SHINE Technologies develops a fusion-based approach to produce medical isotopes such as molybdenum-99, and also plans capability for iodine-131 and xenon-133. The company uses a liquid uranium target that is recycled, which it says reduces radioactive waste volume and operating costs compared with reactor-based production. SHINE has collaborated with U.S. national laboratories for more than 15 years and received technical support and funding from the DOE NNSA. Its commercial Chrysalis facility in Janesville, Wisconsin, is reported to be 75% complete and is positioned to be the world’s largest medical isotope production facility when operational. The recently announced conditional loan commitment from the DOE Office of Energy Dominance Financing is intended to help finish the project and enable market entry. Company leadership and government officials emphasize the project's role in onshoring Mo-99 supply, improving supply-chain reliability, and advancing nonproliferation objectives.

Led · Series B · Jan 2018

PacketFabric provides a software-defined network-as-a-service platform with an API-first portal that provisions services in minutes and a proprietary SDN controller for real-time interaction and automation. The company emphasizes transparent pricing and offers a range of connectivity solutions between colocation facilities, cloud providers, and business partners. PacketFabric is already a leader in 100Gbps Ethernet connectivity for enterprise clients across North America and Europe. The business is part of the NantWorks ecosystem and was developed to support data-intensive use cases such as genomics, AI, healthcare, and media. PacketFabric plans to use a recent $75 million joint venture investment to further develop its technology, add new services and features, and scale availability rapidly across the U.S. and globally. The company is pursuing deeper partner integrations (notably with Cisco) to enable architectures such as SR-MPLS and more agile multi-cloud on-ramp services. PacketFabric is a connectivity-as-a-service platform based in Culver City, CA. It leverages an automated SDN-based network architecture and optical and packet switching technology to enable dynamic, real-time connectivity services between major carrier-neutral colocation facilities at terabit scale. The platform facilitates coast-to-coast connectivity between more than 150 premier colocation facilities across 17 U.S. markets and operates over 150 Points of Presence with a terabit-scale backbone. PacketFabric enables scalable network deployment via an advanced API and a web-based portal. The company recently raised $25m in a Series B and intends to use the funds to grow and expand adoption of its services. PacketFabric is led by newly appointed President and Chief Operating Officer Chad Milam.

Led · Equity · Oct 2015

Precision Biologics is a clinical-stage biotechnology company developing tumor-specific monoclonal antibodies (mAbs) and companion diagnostics for solid-tumor cancers. The company leverages a proprietary library of cancer vaccines, antigens, and antibodies derived from surgically removed human tumors to create therapies intended to activate tumor- and disease-specific immune responses while sparing healthy cells. Its lead therapeutic antibody recently completed accrual to a Phase 2a trial for advanced pancreatic and colorectal cancer, and a multi-center randomized Phase 2b trial for advanced pancreatic cancer is currently enrolling at several U.S. academic medical centers. The pancreatic cancer antibody has demonstrated promising early Phase 2 data and received Orphan Drug status. The pipeline also includes two additional proprietary antibodies that bind tumor-specific antigens found in pancreatic, colorectal and several other types of cancer. Precision Biologics plans to combine its platform with diagnostic and immunotherapy technologies available at NantWorks and NantOmics to accelerate discovery and development.

Led · Equity · Mar 2012

Strand Diagnostics developed the know error® system to perform DNA Specimen Provenance Assignment (DSPA) testing using bar coding, forensic principles and DNA matching before initiating treatment. Launched in 2009, the company says it has conducted prospective DSPA testing on tens of thousands of patients and that hundreds of physicians across specialties have adopted its systems, with breast and prostate biopsy offerings the most popular. Strand reports that roughly 1% of positive cancer diagnoses involve undetected tissue transposition or contamination and that up to 2% of tissue biopsies could result in incorrect diagnoses absent DSPA testing. The company also operates a forensic division, Strand Analytical Laboratories, which supports law enforcement with DNA testing services. The announced capital from NantWorks is intended to accelerate growth, scale operations infrastructure, and expand sales and marketing; the announcement is datelined Indianapolis and Los Angeles.